PharmaShots | Incisive News in 3 Shots

Subscribe Now

Neurogenic Detrusor Overactivity

The US FDA Approves New Indication and Formulation for Astellas' Myrbetriq

The US FDA Approves New Indication and Formulation for Astellas' Myrbetriq

March 26, 2021

Astellas Reports the US FDA's Acceptance of Priority Review for its NDO Therapy

Astellas Reports the US FDA's Acceptance of Priority Review for its NDO Therapy

January 7, 2021

AbbVie Reports the US FDA's Acceptance of BOTOX's sBLA for Pediatric Patients with Neurogenic Detrusor Overactivity

AbbVie Reports the US FDA's Acceptance of BOTOX's sBLA for Pediatric Patients with Neurogenic Detrusor Overactivity

June 23, 2020

Astellas' VESIcare LS (solifenacin succinate) Receives the US FDA's Approval to Treat Neurogenic Detrusor Overactivity (Ndo) In Pediatric Patients Aged 2 Years and Older

Astellas' VESIcare LS (solifenacin succinate) Receives the US FDA's Approval to Treat Neurogenic Detrusor Overactivity (Ndo) In Pe...

May 27, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us